Table 3.
Operative complications, postoperative recurrence, and survival details
| Variables | Values, n (fraction, %) |
|---|---|
| Inflow occlusion time (range), minutes | 10 (10–160) |
| Operating time (minutes) (mean±SD) | 415.6±170.0 |
| (Range) | (240–930) |
| Blood loss (range), mL | 1000 (100–5000) |
| Need PRC transfusions | 7 (38.9%) |
| Range of PRC transfusions (Unit) | 1–10 |
| Length of stay (days) (mean±SD) | 13±4.9 |
| Patient need for intensive care unit | 3 (16.7%) |
| Postoperative complications (Clavien-Dindo grade) | |
| No | 11 (61.1%) |
| I | 2 (2/18, 11.1%) |
| II | 2 (2/18, 11.1%) |
| IIIa | 1 (1/18, 5.6%) |
| Iva | 2 (2/18, 11.1%) |
| 3-month mortality | 0 (0/16) |
| 6-month DFS (%) | 11 (11/18, 61.1%) |
| HCC recurrence | |
| Within 6 months | 8 (8/18, 44.4%) |
| Within 1 year | 11 (11/18, 61.1%) |
| Pattern of recurrence | |
| Intrahepatic recurrence | 6 (54.5%) |
| Lymph node metastasis | 1 (9.0%) |
| Pulmonary metastasis | 3 (27.3%) |
| Peritoneal and bowel metastasis | 1 (9.0%) |
| Treatment after recurrence | |
| Metastectomy | 1 (1/11, 9.0%) |
| TACE/DEI | 6 (6/11, 54.5%) |
| Sorafinib | 2 (2/11, 18.2%) |
| Survival (n) | |
| >1 year | 12 (12/16, 75.0%) |
| >3 years | 6 |
| >5 years | 5 |
| >10 years | 1 |
| 3-year DFS, % (n) | 60.0% (6/10) |
| 3-year OS, % (n) | 60.0% (6/10) |
| Surgical curability from hepatic resection | |
| R0 | 11 (68.7%) |
| R1/R2 | 5 (31.3%) |
Abbreviations: DFS, disease-free survival; HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; DEI, direct ethanol injection; OS, overall survival; PRC, pack red cell.